107 related articles for article (PubMed ID: 23391905)
1. Combined low calcium and lack magnesium is a risk factor for motor deficit in mice.
Taniguchi R; Nakagawasai O; Tan-no K; Yamadera F; Nemoto W; Sato S; Yaoita F; Tadano T
Biosci Biotechnol Biochem; 2013; 77(2):266-70. PubMed ID: 23391905
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Shin JY; Park HJ; Ahn YH; Lee PH
J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
[TBL] [Abstract][Full Text] [Related]
3. L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats.
Alam M; Schmidt WJ
Behav Brain Res; 2004 Aug; 153(2):439-46. PubMed ID: 15265640
[TBL] [Abstract][Full Text] [Related]
4. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
[TBL] [Abstract][Full Text] [Related]
5. Effects of L-dopa and bromocriptine on haloperidol-induced motor deficits in mice.
Kobayashi T; Araki T; Itoyama Y; Takeshita M; Ohta T; Oshima Y
Life Sci; 1997; 61(26):2529-38. PubMed ID: 9416775
[TBL] [Abstract][Full Text] [Related]
6. Effects of L-DOPA on nigral dopamine neurons and local field potential: comparison with apomorphine and muscimol.
Xu D; Karain B; Brantley E; Shi WX
J Pharmacol Exp Ther; 2011 May; 337(2):533-9. PubMed ID: 21330359
[TBL] [Abstract][Full Text] [Related]
7. Effects of low calcium and magnesium dietary intake on the central nervous system tissues of rats and calcium-magnesium related disorders in the amyotrophic lateral sclerosis focus in the Kii Peninsula of Japan.
Yasui M; Ota K; Yoshida M
Magnes Res; 1997 Mar; 10(1):39-50. PubMed ID: 9339837
[TBL] [Abstract][Full Text] [Related]
8. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
Pearce RK; Banerji T; Jenner P; Marsden CD
Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
[TBL] [Abstract][Full Text] [Related]
9. The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA.
Alam M; Mayerhofer A; Schmidt WJ
Behav Brain Res; 2004 May; 151(1-2):117-24. PubMed ID: 15084427
[TBL] [Abstract][Full Text] [Related]
10. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
[TBL] [Abstract][Full Text] [Related]
11. Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels.
Bido S; Marti M; Morari M
J Neurochem; 2011 Sep; 118(6):1043-55. PubMed ID: 21740438
[TBL] [Abstract][Full Text] [Related]
12. [Similarities in calcium and magnesium metabolism between amyotrophic lateral sclerosis and calcification of the spinal cord in the Kii Peninsula ALS focus].
Yasui M; Yoshida M; Tamaki T; Taniguchi Y; Ota K
No To Shinkei; 1997 Aug; 49(8):745-51. PubMed ID: 9282369
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characteristics of catalepsy induced by intracerebroventricular administration of histamine in mice: the importance of muscarinic step in central cholinergic neurons.
Onodera K; Shinoda H
Agents Actions; 1991 May; 33(1-2):143-6. PubMed ID: 1897431
[TBL] [Abstract][Full Text] [Related]
14. Dual effects of L-DOPA on nigral dopaminergic neurons.
Guatteo E; Yee A; McKearney J; Cucchiaroni ML; Armogida M; Berretta N; Mercuri NB; Lipski J
Exp Neurol; 2013 Sep; 247():582-94. PubMed ID: 23481547
[TBL] [Abstract][Full Text] [Related]
15. Are age-related neurodegenerative diseases linked with various types of magnesium depletion?
Durlach J; Bac P; Durlach V; Durlach A; Bara M; Guiet-Bara A
Magnes Res; 1997 Dec; 10(4):339-53. PubMed ID: 9513930
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
[TBL] [Abstract][Full Text] [Related]
17. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
Dominguez-Meijide A; Villar-Cheda B; Garrido-Gil P; Sierrra-Paredes G; Guerra MJ; Labandeira-Garcia JL
Neuropharmacology; 2014 Jan; 76 Pt A():156-68. PubMed ID: 23973568
[TBL] [Abstract][Full Text] [Related]
18. Histamine- and haloperidol-induced catalepsy in aged mice: differential responsiveness to L-DOPA.
Ionov ID; Severtsev NN
Psychopharmacology (Berl); 2012 Sep; 223(2):191-7. PubMed ID: 22526536
[TBL] [Abstract][Full Text] [Related]
19. L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice.
Santini E; Alcacer C; Cacciatore S; Heiman M; Hervé D; Greengard P; Girault JA; Valjent E; Fisone G
J Neurochem; 2009 Feb; 108(3):621-33. PubMed ID: 19187092
[TBL] [Abstract][Full Text] [Related]
20. Paraquat induces selective dopaminergic nigrostriatal degeneration in aging C57BL/6 mice.
Li X; Yin J; Cheng CM; Sun JL; Li Z; Wu YL
Chin Med J (Engl); 2005 Aug; 118(16):1357-61. PubMed ID: 16157030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
